Aptiv Solutions acquires SRA Global Clinical Development
Reston, Va.-based Aptiv Solutions, which designs and executes adaptive clinical trials and medical device studies, has acquired SRA Global Clinical Development (GCD), the CRO division of SRA International, based in Durham, N.C., with offices in Paris, France and Milton Park, England.
With over 15 years in the pharmaceutical and biotech industry, SRA GCD and its predecessor companies have built a substantial business delivering clinical trial and regulatory services around the globe. Aptiv said SRA GCD’s regulatory consulting team, based near London, will add to its regulatory services group.
“We believe the GCD business, as a part of Aptiv Solutions, has greater opportunity to pursue a wider range of initiatives that align with its mission,” said SRA president and CEO Bill Ballhaus.
“We are delighted to welcome the roughly 100 SRA GCD experienced professionals to the Aptiv Solutions team. Our primary focus will be to continue to provide best-in-class service to the current SRA GCD clients,” stated Aptiv Solutions chairman and CEO Pat Donnelly.
Aptiv Solutions is a global biopharmaceutical and medical device development services company that has integrated the resources and expertise of Averion International, Trio Clinical Resourcing, Fulcrum Pharma, ClinResearch, Niphix and ADDPLAN. Its services include adaptive clinical trials, early-phase product strategy, regulatory services, pharmacovigilance and clinical staffing. It has 850 employees in North America, Europe, the Middle East, Japan and Australia.
Fairfax, Va.-based SRA International, which has 7,000 employees, provides technology and strategic consulting services and solutions to government organizations. Founded in 1978, its services include cyber security, disaster response planning, enterprise resource planning, environmental strategies, energy systems and sustainability, IT systems, logistics, public health preparedness and systems engineering.
In March, the company announced its decision to divest its CRO, as well as GCD’s wholly owned subsidiaries. The transaction is effective immediately; financial terms of the deal were not disclosed.